Skip to main content
Clinical Trials/NCT06547138
NCT06547138
Not yet recruiting
Not Applicable

Prospective Descriptive Multicentre Pilot Study On The Effectiveness and Safety Of Optilene® Silver Mesh Elastic In Prevention Of Surgical Site Infection (SSI) And Incisional Hernia (IH)

Aesculap AG5 sites in 1 country110 target enrollmentStarted: March 1, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
110
Locations
5
Primary Endpoint
Surgical Site Infection (SSI) A2/A3 rate

Overview

Brief Summary

The aim of the study is to describe the effectiveness of Optilene® Silver Mesh Elastic on prevention of surgical site infection (SSI) at 6 months follow-up in patients undergoing urgent laparotomy by collecting clinical data on the SSI rates, IH rates and overall clinical performance of Optilene® Silver Mesh Elastic used for the prevention of incisional hernia as prophylactic mesh in patients that require urgent median laparotomy in clinical routine.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patients (18 years or older)
  • Surgical procedure requiring urgent, primary median laparotomy, which are classified as "Class III/Contaminated" or "Class IV/Dirty-Infected" regarding the CDC classification.
  • These include but are not limited to:
  • Vascular surgery
  • Colon and rectum
  • Hepatobiliary
  • Gastrointestinal
  • Gynecology
  • Abdominal Aortic Aneurysm (AAA) repair
  • Right hemicolectomy

Exclusion Criteria

  • Pregnancy
  • Breast feeding
  • Patients \< 18 years old or patients who are still in the growth phase
  • Contaminated and infected areas
  • Hypersensitivity to silver
  • Direct contact with the viscera
  • Previous allergic reactions to components of the device
  • Patient with previous laparotomy
  • Transverse laparotomy
  • Patients with previous hernia repair

Outcomes

Primary Outcomes

Surgical Site Infection (SSI) A2/A3 rate

Time Frame: at 6 months follow-up

SSIs remain a significant clinical problem as they are associated with substantial mortality and morbidity and impose severe demands on healthcare resources. Centers for Disease Control and Prevention Surgical Site Infection (SSI) Classification System differentiates Superficial SSI (A1), Deep Incisional SSI (A2) and Infection with involvement of organs/body cavities (A3). Only cases of A2 and A3 are considered for the Primary Outcome and are compared to rates from reference literature

Secondary Outcomes

  • Cumulative Surgical Site Infection (SSI) A2/A3 rate during the study period(at 1 month, 1 year and 2 year follow-up.)
  • Handling of the Optilene® Silver Mesh Elastic(intraoperatively)
  • Length of hospital stay(at discharge (approximately up to 10 days after surgery))
  • Time to return to work(at all postoperative examinations with a single value for each individual patient)
  • Incisional hernia (IH) rate during the study period(repeatedly at 6 months, 1 year and 2 year follow-up.)
  • Cumulative rate of of postoperative complications during the study period(at discharge (up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up)
  • Development of Pain: Visual Analogue Scale (VAS)(at discharge (approximately up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up, using the VAS score)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (5)

Loading locations...

Similar Trials